inactivated rabies vaccine
Trade name: Imovax
Vaccineapproved
Approved
Jul 1, 1979
The rabies vaccine is a vaccine used to prevent rabies. There are several rabies vaccines available that are both safe and effective. Vaccinations must be administered prior to rabies virus exposure or within the latent period after exposure to prevent the disease. Transmission of rabies virus to humans typically occurs through a bite or scratch from an infectious animal, but exposure can occur through indirect contact with the saliva from an infectious individual. — Wikipedia
Clinical trial activity
67 trials · 63 clinical orgs · 2 marketing orgs
Phase 1
24
Phase 2
41
Phase 3
21
Phase 4
5
Earliest trial started Jun 1, 2003 (NCT00317473)
Timeline
1970s
- Jul 1, 1979
Earliest FDA Approval
1990s
- Oct 20, 1997
Bavarian Nordic — First NDA Organization
- Oct 20, 1997
Bavarian Nordic — NDA Secondary Org
- Oct 20, 1997
Bavarian Nordic — NDA Organization
2000s
- Feb 4, 2000
Sanofi-Aventis — NDA Secondary Org
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2009
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Studied for
- Communicable Diseases · Phase 3
- COVID-19 · Phase 4
- Dengue · Phase 2
- Dengue Virus · Phase 2
- Disease Transmission, Infectious · Phase 1/Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Dysentery, Bacillary · Phase 1/Phase 2
- Encephalitis, Japanese · Phase 3
- Healthy Volunteers · Phase 3
- Immunization · Phase 1/Phase 2
- Lassa Fever · Phase 1
- Malaria · Phase 3
- Malaria, Falciparum · Phase 3
- Mononegavirales Infections · Phase 3
- Neoplasms · Phase 1
- Only Child · Phase 3
- Primary Immunodeficiency Diseases · Phase 4
- Rabies · Phase 4
- Rabies virus · Phase 2
- Rhabdoviridae Infections · Phase 3
- Rift Valley Fever · Phase 2
- RNA Virus Infections · Phase 3
- Severe Dengue · Phase 2
- Vaccines · Phase 3
- Virus Diseases · Phase 4
- Zoonoses · Phase 1/Phase 2
Mechanism of action
- Lyssavirus rabiesImmunity, active
Lyssavirus rabies immunity, active
Approval history
- approvedJul 1, 1979
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRabies vaccine ↗
Also known as
- cell-culture rabies vaccine
- human diploid cell rabies vaccine
- human diploid cell vaccine rabies vaccine
- human rabies vaccine
- imovax
- inactivated rabies virus
- inactivated rabies virus vaccine
- meruvax ii
- rabipur
- rubella virus vaccine, live attenuated, strain ra 27/3 (human diploid fibroblast)
- verocell rabies vaccine
- verorab
- vero rabies vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07124156 | Phase 1 | Mar 20, 2026 | European Vaccine Initiative (EVI), Heidelberg, Germany, Ifakara Health Institute, Luxembourg Institute of Health |
| NCT07055295 | Phase 3 | Mar 1, 2026 | Al-Shifa Trust Eye Hospital, Sinovac Biotech Co., Ltd |
| NCT07055893 | Phase 3 | Mar 1, 2026 | Al-Shifa Trust Eye Hospital, Sinovac Biotech Co., Ltd |
| NCT07168018 | Phase 2 | Dec 31, 2025 | University of Oxford |
| NCT07275645 | Phase 3 | Dec 18, 2025 | Ab&b Biotechnology Co., Ltd. |
| NCT07055880 | Phase 2 | Jul 28, 2025 | Aga Khan University, Sinovac Biotech Co., Ltd |
| NCT07021703 | Phase 1 | May 23, 2025 | AIM Therapeutics Inc. |
| NCT06799234 | Phase 2 | Feb 28, 2025 | University of Oxford |
| NCT06546709 | Phase 1 | Oct 31, 2024 | University of Maryland |
| NCT06548139 | Phase 2 | Jul 31, 2024 | Anning City First People's Hospital, Changchun BCHT Biotechnology Co., Government of China, Yunnan University of Traditional Chinese Medicine |
| NCT06132789 | Phase 1 | Nov 27, 2023 | Ab&b Biotechnology Co., Ltd., Government of China |
| NCT05987384 | N/A | May 3, 2023 | Tsinghua University |
| NCT05832073 | Early Phase 1 (Phase 1) | Apr 30, 2023 | Anning City First People's Hospital, Changchun BCHT Biotechnology Co., Government of China, Yunnan University of Traditional Chinese Medicine |
| NCT05667974 | Phase 3 | Apr 6, 2023 | Yisheng Biopharma |
| NCT05790889 | Phase 1/Phase 2 (Phase 2) | Apr 3, 2023 | European and Developing Countries Clinical Trials Partnership (EDCTP), Institut et Haute école de la Santé, La Source, University of Oxford, Wellcome Trust |
| NCT05776017 | Phase 1/Phase 2 (Phase 2) | Mar 27, 2023 | Malaria Research and Training Center, Bamako, Mali, Vac4All |
| NCT05644067 | Phase 1 | Feb 28, 2023 | Ifakara Health Institute, University of Basel |
| NCT05846568 | Phase 3 | Oct 21, 2022 | Government of China |
| NCT05453487 | Phase 4 | Jul 21, 2022 | Beijing Tiantan Bio Co., Ltd, Changchun Institute of Biological Products Co., Ltd., China National Biotec Group Co., Ltd, Government of China |
| NCT04829630 | N/A | Oct 31, 2021 | Institut Pasteur |
Showing 20 of 67 trials
Page 1 / 4
Organizations
Research & Development (63)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 9 | 7 | 4 | 2003 |
| University of Oxford | Academic/Hospital | 8 | 8 | 3 | 2018 |
| Government of China | Government | 7 | 2 | 4 | 2017 |
| Sanofi-Aventis | For profit | 6 | 3 | 1 | 2012 |
| Ifakara Health Institute | Academic/Hospital | 5 | 0 | 2 | 2018 |
| Malaria Research and Training Center, Bamako, Mali | Academic/Hospital | 5 | 0 | 3 | 2008 |
| Sanofi | For profit | 5 | 5 | 2 | 2009 |
| Synermore Biologics Co., Ltd. | For profit | 4 | 4 | 2 | 2016 |
| Yisheng Biopharma | For profit | 4 | 4 | 3 | 2015 |
| Institut et Haute école de la Santé, La Source | Academic/Hospital | 3 | 0 | 2 | 2017 |
| Kenya Medical Research Institute | Academic/Hospital | 3 | 0 | 2 | 2003 |
| Sinovac Biotech Co., Ltd | For profit | 3 | 3 | 2 | 2025 |
| Wellcome Trust | Academic/Hospital | 3 | 0 | 2 | 2019 |
| Ab&b Biotechnology Co., Ltd. | Academic/Hospital | 2 | 2 | 2 | 2023 |
| African Malaria Network Trust | Academic/Hospital | 2 | 2 | 2 | 2007 |
| Al-Shifa Trust Eye Hospital | Academic/Hospital | 2 | 0 | 1 | 2026 |
| Anning City First People's Hospital | Academic/Hospital | 2 | 0 | 2 | 2023 |
| Changchun BCHT Biotechnology Co. | For profit | 2 | 2 | 2 | 2023 |
| CureVac AG | For profit | 2 | 2 | 1 | 2014 |
| Institut Pasteur | Academic/Hospital | 2 | 1 | 1 | 2015 |
63 organizations
Page 1 / 4
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bavarian Nordic | For profit | NDA2 | Oct 20, 1997 |
| Bavarian Nordic | For profit | NDA | Oct 20, 1997 |
| Sanofi-Aventis | For profit | NDA2 | Feb 4, 2000 |